VivoSeq
Other

Hemoptysis

5

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Hemoptysis is an early-stage landscape with 5 programs across 1 company. The most active players are Amring. 1 therapy is approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Amring

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

7

clinical trials

Completed3 · 43%
Unknown status2 · 29%
Recruiting1 · 14%
Withdrawn1 · 14%

Clinical Trials

Trial Activity

7 trials

ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04961528·315 enrolled
Efficacy of Tranexamic Acid in Hemoptysis
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT02781597·66 enrolled
Tc99m-MAA Bronchial Artery Injection During Bronchial Embolization for Pulmonary Mass Induced Hemoptysis for Dosimetry Planning
Completed·MMassachusetts General Hospital·Phase 1·NCT04105283·8 enrolled
Tranexamic Acid : Nebulization vs IV Route for Hemoptysis
Completed·UUniversity of Health Sciences Lahore·Phase 2/3·NCT07212452·172 enrolled
Effect of Tranexamic Acid on Prevention of Recurrence of Hemoptysis
Withdrawn·SSeoul National University Hospital·Phase 3·NCT01167764
TXA Nebulization for the Treatment of Hemoptysis
Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT05648656·60 enrolled
The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis
Unknown status·MMeir Medical Center·Phase 3·NCT01496196·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)